Diagnostic Performance of [18F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer

Autor: Ramsha Iqbal, Lemonitsa H. Mammatas, Tuba Aras, Wouter V. Vogel, Tim van de Brug, Daniela E. Oprea-Lager, Henk M. W. Verheul, Otto S. Hoekstra, Ronald Boellaard, Catharina W. Menke-van der Houven van Oordt

Publikováno v: Diagnostics, Vol 11, Iss 11, p 1954 (2021)

Positron emission tomography using [18F]fluorodeoxyglucose (FDG PET) potentially underperforms for staging of patients with grade 1–2 estrogen receptor positive (ER+) breast cancer. The aim of this study was to retrospectively investigate the diagn

Externí odkaz: https://doaj.org/article/d8c988063f0c45489f71114b436b3760

Diagnostic performance of [18F]FDG PET in staging grade 1-2, estrogen receptor positive breast cancer

Autor: Catharina W Menke-van der Houven van Oordt, Tim van de Brug, Tuba Aras, Lemonitsa H. Mammatas, Wouter V. Vogel, Ronald Boellaard, Ramsha Iqbal, Daniela E. Oprea-Lager, Otto S. Hoekstra, Henk M.W. Verheul

Publikováno v: Diagnostics; Volume 11; Issue 11; Pages: 1954
Diagnostics, 11
Diagnostics
Diagnostics, Vol 11, Iss 1954, p 1954 (2021)
Iqbal, R, Mammatas, L H, Aras, T, Vogel, W V, van de Brug, T, Oprea-Lager, D E, Verheul, H M W, Hoekstra, O S, Boellaard, R & Menke-van der Houven van Oordt, C W 2021, ' Diagnostic performance of [18 f]fdg pet in staging grade 1–2, estrogen receptor positive breast cancer ', Diagnostics (Basel, Switzerland), vol. 11, no. 11, 1954 . https://doi.org/10.3390/diagnostics11111954
Diagnostics, 11, 11
Diagnostics (Basel, Switzerland), 11(11):1954. MDPI AG

BackgroundAccurate staging of early breast cancer (BC) patients is essential for tailored treatment. Currently, the preferred imaging modality for staging is positron emission tomography with [18F]Fluorodeoxyglucose (FDG PET) combined with a diagnost

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be8552479f28a5c5627b3ec6164528a
https://doi.org/10.21203/rs.3.rs-695998/v1

Visual and quantitative evaluation of [F-18]FES and [F-18]FDHT PET in patients with metastatic breast cancer

Autor: Geke A. P. Hospers, Clasina M Venema, Henrica C. W. de Vet, Michel van Kruchten, Elisabeth G.E. de Vries, Epie Boven, Maqsood Yaqub, C. Willemien Menke-van der Houven van Oordt, Henk M.W. Verheul, Lemonitsa H. Mammatas, Erik F. J. de Vries, Otto S. Hoekstra, Carolina P. Schröder, Bert van der Vegt, Andor W. J. M. Glaudemans

Publikováno v: Ejnmmi Research, 10, 1
EJNMMI Research
EJNMMI Research, 10(1):40. Springer Berlin
EJNMMI Research, 10(1):40. SpringerOpen
EJNMMI Research, Vol 10, Iss 1, Pp 1-12 (2020)
Mammatas, L H, Venema, C M, Schröder, C P, de Vet, H C W, van Kruchten, M, Glaudemans, A W J M, Yaqub, M M, Verheul, H M W, Boven, E, van der Vegt, B, de Vries, E F J, de Vries, E G E, Hoekstra, O S, Hospers, G A P & der Houven van Oordt, C W M V 2020, ' Visual and quantitative evaluation of [ 18 F]FES and [ 18 F]FDHT PET in patients with metastatic breast cancer : an interobserver variability study ', EJNMMI Research, vol. 10, no. 1, 40 . https://doi.org/10.1186/s13550-020-00627-z
Ejnmmi Research, 10

Purpose Correct identification of tumour receptor status is important for treatment decisions in breast cancer. [18F]FES PET and [18F]FDHT PET allow non-invasive assessment of the oestrogen (ER) and androgen receptor (AR) status of individual lesions

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5da73d1ee305ab1a1599386178703b5e
https://doi.org/10.1186/s13550-020-00627-z

Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies

Autor: Erik F. J. de Vries, Alphons H. H. Bongaerts, Andor W. J. M. Glaudemans, Elisabeth G.E. de Vries, Lemonitsa H. Mammatas, Michel van Kruchten, Geke A. P. Hospers, Otto S. Hoekstra, Epie Boven, Catharina W Menke-van der Houven van Oordt, Clasina M Venema, Ronald Boellaard, Giulia Apollonio, Carolina P. Schröder, Bert van der Vegt, Henk M.W. Verheul

Publikováno v: Venema, C M, Mammatas, L H, Schröder, C P, van Kruchten, M, Apollonio, G, Glaudemans, A W J M, Bongaerts, A H H, Hoekstra, O S, Verheul, H M W, Boven, E, van der Vegt, B, de Vries, E F, de Vries, E G E, Boellaard, R, Menke-van der Houven van Oordt, C W & Hospers, G A 2017, ' Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies ', Journal of Nuclear Medicine, vol. 58, no. 12, pp. 1906-1912 . https://doi.org/10.2967/jnumed.117.193649
Journal of Nuclear Medicine, 58(12), 1906-1912. Society of Nuclear Medicine Inc.
Journal of Nuclear Medicine, 58(12), 1906-1912. SOC NUCLEAR MEDICINE INC

In addition to the well-known estrogen receptor (ER) and human epidermal growth factor receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer treatment. Whole-body imaging can provide information across lesions within

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57c9c78b716f27b2285970d30bad2e4d
https://doi.org/10.2967/jnumed.117.193649

Abstract 1415: Staging with [18F]FDG PET/CT

Autor: Ramsha Iqbal, Lemonitsa H. Mammatas, Wouter V. Vogel, Catharina W Menke-van der Houven van Oordt, H. M. W. Verheul, Daniela E. Oprea-Lager, Tuba Aras, Ronald Boellaard

Publikováno v: Cancer Research. 79:1415-1415

Background: Accurate staging of patients with primary breast cancer is essential for an optimal treatment plan. The current imaging standard for staging, positron emission tomography/computed tomography with [18F]Fluorodeoxyglucose ([18F]FDG PET/CT),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2231b780b56098e9e4535e8b12be3e83
https://doi.org/10.1158/1538-7445.am2019-1415